BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP- 812 Aspa’s Investigational Gene Therapy for Canavan Disease

We’re thrilled to announce that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BBP-812, Aspa’s investigational AAV9 gene therapy for Canavan disease. We are committed to working closely with the FDA and the Canavan community to develop BBP-812 as fast as possible to address the unmet medical needs of individuals with Canavan disease. Learn about RMAT designation on the FDA’s website by visiting this link: https://rb.gy/spz8qs